COVID-19 triggered atypical hemolytic uremic syndrome (aHUS) in a 13-year-old boy with a genetic predisposition to the syndrome, a recent case study reports. Treatment with plasma exchange therapy, a type of blood-cleansing procedure, was effective, and the boy fully recovered. “This case highlights the potential of COVID-19 to trigger…
News
A previously healthy 20-year-old woman developed atypical hemolytic uremic syndrome (aHUS) after having surgery to remove her gallbladder shortly after giving birth, according to a recent case study. The woman was treated successfully with Soliris (eculizumab) and with no complications. The case shows “minimally invasive surgeries done within…
Under a new commercialization agreement with Samsung Bioepis, the developer of Epysqli (eculizumab-aagh), Teva Pharmaceuticals will have exclusive marketing rights in the U.S. for the Soliris (eculizumab) biosimilar — an approved treatment for atypical hemolytic uremic syndrome (aHUS). A biosimilar is a biological product that is highly similar to…
The use of a C5 inhibitor — with or without plasma exchange — was found to work better than supportive care to treat kidney problems in women who develop atypical hemolytic uremic syndrome (aHUS) as a complication of bleeding after giving birth, a study found. However, the researchers noted…
Disease manifestations that affect the brain, such as seizures, are relatively common with atypical hemolytic uremic syndrome (aHUS), as are digestive symptoms and heart-related problems, a study finds. The study, “Extrarenal manifestations of atypical hemolytic uremic syndrome: a systematic review and meta-analysis,” was published in Pediatric…
A 38-year-old woman in Portugal developed atypical hemolytic uremic syndrome (aHUS) despite showing no typical markers of the disease after she experienced gastrointestinal inflammation, according to a case report. “This case highlights the diagnostic and management challenges in aHUS when traditional disease markers are absent and emphasizes the importance…
Physicians in India described the case of atypical hemolytic uremic syndrome (aHUS) that manifested as loss of vision in one eye in a 30-year-old man. The patient was successfully managed with plasma therapy, because Soliris (eculizumab) was not available. “This is the first described case to our knowledge…
It may be safe for some adults with atypical hemolytic uremic syndrome (aHUS) to discontinue treatment once they’re clinically stable, but a decision depends on a complex group of factors, a study based on interviews with aHUS experts indicates. The patient’s health status, personal preferences, and access to close…
A weight-based regimen for administering Soliris (eculizumab) in people with atypical hemolytic uremic syndrome (aHUS) may allow patients to reach therapeutic levels of the medication with fewer infusions, saving time and money. “We suggest to introduce this dosing schedule as the standard of care to improve therapeutic success…
A 60-year-old man with atypical hemolytic uremic syndrome (aHUS) was successfully treated with Soliris (eculizumab) using a personalized dosing regimen based on clinical responses, according to a recent case study. Clinicians lowered the dose of the medication in parallel with clinical improvements and eventually discontinued treatment instead of…
Recent Posts
- How aHUS treatment led to my first tattoos
- Ultomiris at lower doses just as safe, effective for children with aHUS: Study
- Strange symptoms make me wonder if I’m having neurological complications
- Leaky artificial heart valve triggers rare aHUS in woman, 70: Report
- How my body naturally reacts to one of my bad habits
- Study finds alternative pathway is main driver of aHUS
- Rapid, sustained aHUS response seen with Ultomiris in real-world data
- Team care saves mother with trio of postpartum complications
- Once a good side hustle, donating plasma is now too risky for me
- Treatment halts aHUS recurrence after COVID-triggered relapse